Status:
COMPLETED
Platelet Rich Plasma for Patients With Recurrent Implantation Failure
Lead Sponsor:
Stanford University
Conditions:
Infertility
Eligibility:
FEMALE
18-45 years
Phase:
EARLY_PHASE1
Brief Summary
Patients with recurrent implantation failure are among the most difficult patients to treat, with no proven standard treatment. Platelet rich plasma stimulates cellular processes involved in endometri...
Detailed Description
Patients considered to have recurrent implantation failure will undergo randomization to receive intrauterine infusions of platelet rich plasma or a placebo of embryo culture media prior to their embr...
Eligibility Criteria
Inclusion
- All women who have undergone 3 or more embryo (blastocyst stage) transfers without establishing a clinical pregnancy or 2 or more euploid embryo transfers without establishing a clinical pregnancy, aged 18 - 45, with a normal uterine cavity established within 12 months by hysteroscopy or saline infusion sonogram, planning in vitro fertilization with an embryo transfer at Stanford Fertility and Reproductive Health. The planned transfer must consist of any of the following: a PGS proven euploid embryo, a good quality blastocyst from a patient younger than 37, or a donor oocyte blastocyst.
Exclusion
- Abnormal uterine cavity, planning in vitro fertilization with use of a gestational carrier. patients enrolled in other experimental interventions for RIF will be excluded. Patients with only poor quality or cleavage stage embryos.
Key Trial Info
Start Date :
January 16 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 20 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03379649
Start Date
January 16 2019
End Date
December 20 2023
Last Update
December 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford Fertility and Reproductive Health
Sunnyvale, California, United States, 94087